The U.S. Centers for Disease Control and Prevention has made its decision for the Johnson & Johnson vaccine, which was discontinued on April 13 on suspicion of causing blood clotting. The CDC said the vaccine should continue to be used because its benefits out more than its risks.
In the US, Johnson & Johnson’s vaccine against the coronavirus was discontinued on April 13 on suspicion of causing blood clotting.
The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Vaccination Practices met to decide whether to continue using the vaccine in the country. The committee voted 4-10 to proceed with Johnson & Johnson’s use of the Covid-19 vaccine.
Committee members noted that the benefits of the vaccine outweighed the risks associated with blood clotting associated with the vaccine, and recommended continued use in the country.
EFFECTIVENESS RATE 66 PERCENT
The Johnson & Johnson vaccine will add a warning that it causes blood clotting, it said, adding that it is recommended for use in people 18 and older under the U.S. Food and Drug Administration’s (FDA) emergency use authority. Johnson &Johnson received the first single-dose Covid-19 vaccine approved in the U.S., with an overall efficacy rate of 66 percent.
The Johnson & Johnson vaccine, which has been raised with the issue of blood clotting, such as the Oxford-AstraZeneca vaccine, has also been plagued by scandals in the manufacturing process. Millions of doses of vaccines failed quality-control tests at the factory in Baltimore, where components for coronavirus vaccines were manufactured by Emergent BioSolutions.
The plant produced both AstraZeneca and Johnson & Johnson vaccines while mixing components of single-dose Johnson & Johnson vaccines. Therefore, while the Johnson & Johnson vaccines became unusable, it was learned that 15 million doses of the vaccine were affected and went to waste.
Despite the shortage, the goal of producing 100 million doses of vaccines will be met by the end of May, Johnson & Johnson said in a statement. The number of doses the company plans to produce by the end of 2021 was announced as 1 billion doses.